Alex Iranzo1, Paula Marrero-González2, Mónica Serradell2, Carles Gaig2, Joan Santamaria2, Isabel Vilaseca3. 1. Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED: CB06/05/0018-ISCIII, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain. airanzo@clinic.cat. 2. Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED: CB06/05/0018-ISCIII, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain. 3. Otorhinolaryngology Service, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBER Enfermedades Respiratorias, Bunyola, Spain.
Abstract
OBJECTIVE: To determine if hyposmia in isolated REM sleep behavior disorder (IRBD) predicts short-term conversion to any α-synucleinopathy and declines with time. METHODS: Olfaction was tested using the University of Pennsylvania Smell Identification Test (UPSIT-40) in 140 consecutive patients with polysomnography-confirmed IRBD and in 77 matched controls. Patients were followed-up during 5.6 ± 3.9 (range 0.2-13) years. Twenty-one patients underwent serial UPSIT-40 evaluations at 1-3 and 4-6 years after baseline. RESULTS: UPSIT-40 score was lower in patients than in controls (20.2 ± 6.5 vs. 28.6 ± 5.0; p < 0.001). Hyposmia (UPSIT-40 score < 19 points) occurred in 42.9% patients. Forty-three (30.7%) patients developed Parkinson disease (PD = 27), dementia with Lewy bodies (DLB = 13) and multiple system atrophy (MSA = 3). Kaplan-Meier analysis showed that hyposmics had higher risk than normosmics to develop a synucleinopathy at the short term (p = 0.030). UPSIT-40 score was similar between patients who developed PD and DLB (p = 0.136). Normal smell occurred in all three (100%) IRBD patients who developed MSA, 12 of 27 (44%) who developed PD, and 4 of 13 (31%) that developed DLB. Serial UPSIT-40 evaluations showed no changes with time (p = 0.518). CONCLUSION: In IRBD, hyposmia is a short-term risk for synucleinopathies but cannot distinguish underlying PD from DLB. Normosmia not only occurs in latent MSA but also in latent PD and DLB. In future IRBD neuroprotective trails, individuals at entry could be enriched for hyposmia, whereas serial evaluation of smell would not be useful to monitor the efficacy of a therapeutic intervention.
OBJECTIVE: To determine if hyposmia in isolated REM sleep behavior disorder (IRBD) predicts short-term conversion to any α-synucleinopathy and declines with time. METHODS: Olfaction was tested using the University of Pennsylvania Smell Identification Test (UPSIT-40) in 140 consecutive patients with polysomnography-confirmed IRBD and in 77 matched controls. Patients were followed-up during 5.6 ± 3.9 (range 0.2-13) years. Twenty-one patients underwent serial UPSIT-40 evaluations at 1-3 and 4-6 years after baseline. RESULTS: UPSIT-40 score was lower in patients than in controls (20.2 ± 6.5 vs. 28.6 ± 5.0; p < 0.001). Hyposmia (UPSIT-40 score < 19 points) occurred in 42.9% patients. Forty-three (30.7%) patients developed Parkinson disease (PD = 27), dementia with Lewy bodies (DLB = 13) and multiple system atrophy (MSA = 3). Kaplan-Meier analysis showed that hyposmics had higher risk than normosmics to develop a synucleinopathy at the short term (p = 0.030). UPSIT-40 score was similar between patients who developed PD and DLB (p = 0.136). Normal smell occurred in all three (100%) IRBD patients who developed MSA, 12 of 27 (44%) who developed PD, and 4 of 13 (31%) that developed DLB. Serial UPSIT-40 evaluations showed no changes with time (p = 0.518). CONCLUSION: In IRBD, hyposmia is a short-term risk for synucleinopathies but cannot distinguish underlying PD from DLB. Normosmia not only occurs in latent MSA but also in latent PD and DLB. In future IRBD neuroprotective trails, individuals at entry could be enriched for hyposmia, whereas serial evaluation of smell would not be useful to monitor the efficacy of a therapeutic intervention.
Entities:
Keywords:
Dementia with lewy bodies; Hyposmia; Parkinson disease; REM sleep behavior disorder; Synucleinopathy; UPSIT-40
Authors: Alain Ndayisaba; Ariana T Pitaro; Andrew S Willett; Kristie A Jones; Claudio Melo de Gusmao; Abby L Olsen; Jisoo Kim; Eero Rissanen; Jared K Woods; Sharan R Srinivasan; Anna Nagy; Amanda Nagy; Merlyne Mesidor; Steven Cicero; Viharkumar Patel; Derek H Oakley; Idil Tuncali; Katherine Taglieri-Noble; Emily C Clark; Jordan Paulson; Richard C Krolewski; Gary P Ho; Albert Y Hung; Anne-Marie Wills; Michael T Hayes; Jason P Macmore; Luigi Warren; Pamela G Bower; Carol B Langer; Lawrence R Kellerman; Christopher W Humphreys; Bonnie I Glanz; Elodi J Dielubanza; Matthew P Frosch; Roy L Freeman; Christopher H Gibbons; Nadia Stefanova; Tanuja Chitnis; Howard L Weiner; Clemens R Scherzer; Sonja W Scholz; Dana Vuzman; Laura M Cox; Gregor Wenning; Jeremy D Schmahmann; Peter Novak; Geoffrey S Young; Mel B Feany; Tarun Singhal; Vikram Khurana Journal: Cerebellum Date: 2022-10-03 Impact factor: 3.648
Authors: Mitchell G Miglis; Charles H Adler; Elena Antelmi; Dario Arnaldi; Luca Baldelli; Bradley F Boeve; Matteo Cesari; Irene Dall'Antonia; Nico J Diederich; Kathrin Doppler; Petr Dušek; Raffaele Ferri; Jean-François Gagnon; Ziv Gan-Or; Wiebke Hermann; Birgit Högl; Michele T Hu; Alex Iranzo; Annette Janzen; Anastasia Kuzkina; Jee-Young Lee; Klaus L Leenders; Simon J G Lewis; Claudio Liguori; Jun Liu; Christine Lo; Kaylena A Ehgoetz Martens; Jiri Nepozitek; Giuseppe Plazzi; Federica Provini; Monica Puligheddu; Michal Rolinski; Jan Rusz; Ambra Stefani; Rebekah L S Summers; Dallah Yoo; Jennifer Zitser; Wolfgang H Oertel Journal: Lancet Neurol Date: 2021-08 Impact factor: 44.182